C
Christopher A. Eide
Researcher at Oregon Health & Science University
Publications - 105
Citations - 7170
Christopher A. Eide is an academic researcher from Oregon Health & Science University. The author has contributed to research in topics: Myeloid leukemia & Dasatinib. The author has an hindex of 33, co-authored 97 publications receiving 5713 citations. Previous affiliations of Christopher A. Eide include Howard Hughes Medical Institute.
Papers
More filters
Journal ArticleDOI
AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
Thomas O'Hare,Thomas O'Hare,William C. Shakespeare,Xiaotian Zhu,Christopher A. Eide,Christopher A. Eide,Victor M. Rivera,Frank Wang,Lauren T. Adrian,Lauren T. Adrian,Tianjun Zhou,Huang Wei Sheng,Qihong Xu,Chester A. Metcalf,Jeffrey W. Tyner,Marc M. Loriaux,Amie S. Corbin,Amie S. Corbin,Scott Wardwell,Yaoyu Ning,Jeffrey A. Keats,Yihan Wang,Raji Sundaramoorthi,Mathew Thomas,Dong Zhou,Joseph Snodgrass,Lois Commodore,Tomi K. Sawyer,David C. Dalgarno,Michael W. Deininger,Brian J. Druker,Brian J. Druker,Tim Clackson +32 more
TL;DR: Design and preclinical evaluation of AP24534, a potent, orally available multitargeted kinase inhibitor active against T315I and other BCR-ABL mutants, and clinical evaluation ofAP24534 as a pan-BCR-ABl inhibitor for treatment of CML are reported.
Journal ArticleDOI
Functional genomic landscape of acute myeloid leukaemia
Jeffrey W. Tyner,Cristina E. Tognon,Cristina E. Tognon,Daniel Bottomly,Beth Wilmot,Stephen E. Kurtz,Samantha L. Savage,Nicola Long,Anna Reister Schultz,Elie Traer,Melissa L. Abel,Anupriya Agarwal,Aurora Blucher,Uma Borate,Jade Bryant,Russell T. Burke,Amy S. Carlos,Richie Carpenter,Joseph Carroll,Bill H. Chang,Cody Coblentz,Amanda d’Almeida,Rachel J. Cook,Alexey V. Danilov,Kim Hien T. Dao,Michie Degnin,Deirdre Devine,James Dibb,David K. Edwards,Christopher A. Eide,Christopher A. Eide,Isabel English,Jason M. Glover,Rachel Henson,Hibery Ho,Abdusebur Jemal,Kara Johnson,Ryan C. Johnson,Brian Junio,Andy Kaempf,Jessica Leonard,Chenwei Lin,Selina Qiuying Liu,Pierrette Lo,Marc M. Loriaux,Samuel B. Luty,Tara A. Macey,Jason D. MacManiman,Jacqueline Martinez,Motomi Mori,Dylan Nelson,Ceilidh Nichols,Jill Peters,Justin Ramsdill,Angela Rofelty,Robert Schuff,Robert P. Searles,Erik Segerdell,Rebecca Smith,Stephen E. Spurgeon,Tyler Sweeney,Aashis Thapa,Corinne Visser,Jake Wagner,Kevin Watanabe-Smith,Kristen Werth,Joelle Wolf,Libbey White,Amy Yates,Haijiao Zhang,Christopher R. Cogle,Robert H. Collins,Denise C. Connolly,Michael W. Deininger,Leylah Drusbosky,Christopher S. Hourigan,Craig T. Jordan,Patricia Kropf,Tara L. Lin,Micaela E. Martinez,Bruno C. Medeiros,Rachel R. Pallapati,Daniel A. Pollyea,Ronan T. Swords,Justin M. Watts,Scott Weir,David L. Wiest,Ryan M. Winters,Shannon K. McWeeney,Brian J. Druker,Brian J. Druker +90 more
TL;DR: Analyses of samples from patients with acute myeloid leukaemia reveal that drug response is associated with mutational status and gene expression; the generated dataset provides a basis for future clinical and functional studies of this disease.
Journal ArticleDOI
Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia
TL;DR: The potential of Abl kinase inhibitor combinations to induce stable responses even in advanced CML and interpret the emerging data in the context of CML pathogenesis is assessed.
Journal ArticleDOI
Oncogenic CSF3R Mutations in Chronic Neutrophilic Leukemia and Atypical CML
Julia E. Maxson,Jason Gotlib,Daniel A. Pollyea,Angela G. Fleischman,Anupriya Agarwal,Christopher A. Eide,Christopher A. Eide,Daniel Bottomly,Beth Wilmot,Shannon K. McWeeney,Cristina E. Tognon,Cristina E. Tognon,J. Blake Pond,Robert H. Collins,Basem S. Goueli,Stephen T. Oh,Michael W. Deininger,Bill H. Chang,Marc M. Loriaux,Brian J. Druker,Brian J. Druker,Jeffrey W. Tyner +21 more
TL;DR: In this paper, the authors used an integrated approach of deep sequencing coupled with the screening of primary leukemia cells obtained from patients with CNL or atypical CML against panels of tyrosine kinase-specific small interfering RNAs or small-molecule kinase inhibitors.
Journal ArticleDOI
Activating alleles of JAK3 in acute megakaryoblastic leukemia
Denise K. Walters,Denise K. Walters,Thomas Mercher,Ting-Lei Gu,Thomas O'Hare,Thomas O'Hare,Jeffrey W. Tyner,Marc M. Loriaux,Valerie Goss,Kimberly Lee,Christopher A. Eide,Matthew J. Wong,Eric P. Stoffregen,Laura McGreevey,Julie Nardone,Sandra A. Moore,John D. Crispino,Titus J. Boggon,Michael Heinrich,Michael Heinrich,Michael W. Deininger,Roberto D. Polakiewicz,D. Gary Gilliland,Brian J. Druker,Brian J. Druker +24 more
TL;DR: A screening strategy that rapidly identifies tyrosine-phosphorylated proteins using mass spectrometry allowed the identification of an activating mutation (A572V) in the JAK3 pseudokinase domain in the acute megakaryoblastic leukemia (AMKL) cell line CMK.